BioSpace News Archive

Bloom Science, Inc., a clinical-stage, central nervous system (CNS) company focused on discovering and developing breakthrough therapeutics that target the Gut-Brain Axis, today announced that the company has completed enrollment in all four cohorts of healthy adult participants as part of its Phase 1 clinical trial.

In new research, scientists at The Feinstein Institutes for Medical Research have shown the ability to reduce pancreatic inflammation by stimulating the vagus nerve using optogenetics, or light.

Alcami Corporation, a leading contract development and manufacturing organization, announced the completion of Phase III expansion of its cGMP biostorage facility located in Amherst, New Hampshire.

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (FSE: A2JMZC) (“Khiron” or the “Company”), welcomes the clear affirmation of the Federal Joint Committee (G-BA) regarding the future of medical cannabis in Germany as a treatment option reimbursed by statutory health insurance (SHI).

BD, a leading global medical technology company, announced that it has been recognized by Forbes as one of the leading employers in the U.S. for diversity.

The Insight Partners published latest research report on “Immunohistochemistry Market Revenue Report, Size, Share, Growth, Trends & Forecast to 2028 - COVID-19 Impact and Global Analysis By Application; Product; End User and Geography.”,

Aetion®, the global leader in real-world evidence (RWE) technology and analytics, is pleased to announce the culmination of the RCT-DUPLICATE demonstration project, with complete findings published today in The Journal of the American Medical Association (JAMA).

The American Urological Association, in partnership with the Society of Urologic Oncology, released the 2023 clinical practice guideline on the early detection of prostate cancer.

Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2023 clinical practice guideline for the diagnosis and management of non-metastatic upper tract urothelial carcinoma (UTUC).

Median Technologies (ALMDT:PA) announced today that the two webcasts during which Fredrik Brag, CEO and Founder will provide a corporate update, are rescheduled from May 3rd to May 4th, 2023.